Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02092961 · ClinicalTrials.gov registry record · Phase 2
Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
NCT02092961 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 198 participants.
The verdict
NCT02092961, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
Study Summary
This is a sub-study of the OSKIRA-4 study, (D4300C0004, NCT01264770) to explore alternative and more sensitive modalities for measuring the beneficial effects of syk inhibition with fostamatinib in patients with active RA. This MRI sub-study was reported later than the main study due to recruitment delays at specialist imaging sites and so is registered and presented entirely separately to the main study results. This study will investigate the impact of treatment on joint activity and damage by assessing synovitis, osteitis, bone erosions and joint space narrowing.
Interventions
- DRUG Adalimumab
- DRUG Fostamatinib
- DRUG Placebo of Fostamatinib
- DRUG Placebo of Adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02092961
The ClinicalTrials.gov registry entry for NCT02092961 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Adalimumab is the first listed.
NCT02092961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02092961 about?
NCT02092961 is a clinical study titled "Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study". This is a sub-study of the OSKIRA-4 study, (D4300C0004, NCT01264770) to explore alternative and more sensitive modalities for measuring the beneficial effects of syk inhibition with fostamatinib in patients with active RA. This MRI sub-study was reported later than the main study due to recruitment ...
What is the current status of trial NCT02092961?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2011-02. Estimated completion is 2013-07.
What interventions are being tested in trial NCT02092961?
The interventions under investigation include: Adalimumab (DRUG), Fostamatinib (DRUG), Placebo of Fostamatinib (DRUG), Placebo of Adalimumab (DRUG).
Who is sponsoring clinical trial NCT02092961?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.